BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
65.29
-0.32 (-0.49%)
At close: Aug 27, 2026, 4:00 PM EDT
64.00
-1.29 (-1.98%)
After-hours: Aug 27, 2026, 5:28 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $91.04. The average 1-year stock price forecast is 39.44% higher than the current stock price, while the lowest is $59 (-9.63%) and the highest is $124 (+89.92%).
Price Target: $91.04 (+39.44%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 13 | 14 |
| Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Hold | 5 | 5 | 6 | 6 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 26 | 26 | 25 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $88 | Buy | Maintains | $88 | +34.78% | Aug 26, 2026 |
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 19, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $114 | Buy | Reiterates | $114 | +74.61% | Aug 19, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $86 | Buy | Maintains | $86 | +31.72% | Aug 19, 2026 |
Unknown Analyst BMO Capital No rating | BMO Capital | Buy Initiates $98 | Buy | Initiates | $98 | +50.10% | Aug 18, 2026 |
Financial Forecast
Revenue This Year
3.91B
from 3.22B
Increased by 21.25%
Revenue Next Year
4.45B
from 3.91B
Increased by 14.00%
EPS This Year
5.02
from 3.15
Increased by 59.52%
EPS Next Year
6.47
from 5.02
Increased by 28.80%
EPS and Forward PE are based on non-GAAP adjusted numbers.